StreetInsider.com News Articles

Gossamer Bio Inc. (GOSS) PT Lowered to $5 at H.C. Wainwright

Fri, 06 Mar 2026 06:49:25 -0500

H.C. Wainwright analyst Patrick Trucchio lowered the price target on Gossamer Bio Inc. (NASDAQ: GOSS) to $5.00 (from $10.00) while maintaining a Buy rating.

Gossamer Bio Inc. (GOSS) PT Lowered to $3 at Oppenheimer

Thu, 05 Mar 2026 08:50:52 -0500

Oppenheimer analyst Andreas Argyrides lowered the price target on Gossamer Bio Inc. (NASDAQ: GOSS) to $3.00 (from $12.00) while maintaining a Outperform rating.

Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: 683 Capital Management, LLC

Mon, 02 Mar 2026 11:58:00 -0500

si-local-file:///var/storage/secattach/20260302/26089836.html

Form SCHEDULE 13G Gossamer Bio, Inc. Filed by: 683 Capital Management, LLC

Mon, 02 Mar 2026 11:58:00 -0500

si-local-file:///var/storage/secattach/20260302/26089836.html

Gossamer Bio Inc. (GOSS) PT Lowered to $0.50 at Goldman Sachs

Wed, 25 Feb 2026 06:35:13 -0500

Goldman Sachs analyst Paul Choi lowered the price target on Gossamer Bio Inc. (NASDAQ: GOSS) to $0.50 (from $8.00) while maintaining a Neutral rating.

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: Growth Equity Opportunities 18 VGE, LLC

Tue, 24 Feb 2026 19:21:00 -0500

si-local-file:///var/storage/secattach/20260224/26053690.html

Form SCHEDULE 13D/A Gossamer Bio, Inc. Filed by: Growth Equity Opportunities 18 VGE, LLC

Tue, 24 Feb 2026 19:21:00 -0500

si-local-file:///var/storage/secattach/20260224/26053690.html

Wedbush Downgrades Gossamer Bio Inc. (GOSS) to Neutral

Tue, 24 Feb 2026 07:03:41 -0500

Wedbush analyst Laura Chicho downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to Neutral with a price target of $1.00.

The analyst comments "Downgrading to Neutral. Simply put, PROSERA data fell short of expectations and while there will be an opportunity for additional FRI results to emerge, the key question in our view is can a registrational path be found for seralutinib? We continue to assume the answer is yes;

Wedbush Downgrades Gossamer Bio Inc. (GOSS) to Neutral

Tue, 24 Feb 2026 07:03:41 -0500

Wedbush analyst Laura Chicho downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to Neutral with a price target of $1.00.

Barclays Downgrades Gossamer Bio Inc. (GOSS) to Underweight

Tue, 24 Feb 2026 04:34:37 -0500

Barclays analyst Eliana Merle downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Overweight to Underweight with a price target of $0.30 (from $9.00).

The analyst comments: "We downgrade GOSS from Overweight to Underweight and adjust our PT from $9/sh to $0.30/sh after Ph3 data from the PROSERA trial in PAH reported the morning of 2/23. We think this is an unfortunate situation highlighting the challenges of drug development, even with an active drug that could be meaningful for patients, but from a stock perspective we see challenges with a debt balance higher than current cash (outstanding ~$200m in June 2027 convertible

Barclays Downgrades Gossamer Bio Inc. (GOSS) to Underweight

Tue, 24 Feb 2026 04:34:37 -0500

Barclays analyst Eliana Merle downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Overweight to Underweight with a price target of $0.30 (from $9.00).

Leerink Partners Downgrades Gossamer Bio Inc. (GOSS) to Market Perform

Tue, 24 Feb 2026 00:43:56 -0500

Leerink Partners analyst Joseph Schwartz downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to Market Perform with a price target of $1.00 (from $6.00).

The analyst comments: "GOSS announced disappointing Ph.3 PROSERA results this morning, missing statistical significance on the primary endpoint of 6MWD (six-minute walk distance). We are downgrading the stock to Market Perform pending greater clarity on the path forward for seralutinib. As we highlighted earlier (link), this outcome falls within our bear case scenario with a 6MWD of +13.3M vs. placebo. While the drug appears to be active and there are positive elements of the data such as

Leerink Partners Downgrades Gossamer Bio Inc. (GOSS) to Market Perform

Tue, 24 Feb 2026 00:43:56 -0500

Leerink Partners analyst Joseph Schwartz downgraded Gossamer Bio Inc. (NASDAQ: GOSS) from Outperform to Market Perform with a price target of $1.00 (from $6.00).

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Mon, 23 Feb 2026 12:40:00 -0500

BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Gossamer Bio, Inc. (Nasdaq: GOSS) for potential securities law violations. Investors who have lost money in their Gossamer Bio, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/goss.

What is this all about?

Shares of Gossamer Bio fell more than 75% on February 23, 2026, after the company announced that its Phase 3 PROSERA trial evaluating seralutinib in pulmonary arterial hypertension failed to meet its primary

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Mon, 23 Feb 2026 12:40:00 -0500

What is this all about?

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Mon, 23 Feb 2026 12:40:00 -0500

What is this all about?

BREAKING: Gossamer Bio Investors Should Contact Block & Leviton to Potentially Recover Losses After Shares Fall Over 75%

Mon, 23 Feb 2026 12:40:00 -0500

What is this all about?

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mon, 23 Feb 2026 11:26:00 -0500

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Gossamer Bio, Inc. (NASDAQ: GOSS). The investigation focuses on Gossamer’s executive officers and whether investor losses may be recovered under federal securities laws.

What if I purchased Gossamer Bio securities?

If you purchased Gossamer Bio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619)

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mon, 23 Feb 2026 11:26:00 -0500

What if I purchased Gossamer Bio securities?

If you purchased Gossamer Bio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619)

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mon, 23 Feb 2026 11:26:00 -0500

What if I purchased Gossamer Bio securities?

If you purchased Gossamer Bio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619)

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Mon, 23 Feb 2026 11:26:00 -0500

What if I purchased Gossamer Bio securities?

If you purchased Gossamer Bio securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Click here to join the investigation.

Or for more information, contact Jim Baker at jimb@johnsonfistel.com or (619)

Form 8-K Gossamer Bio, Inc. For: Feb 23

Mon, 23 Feb 2026 08:30:00 -0500

si-local-file:///var/storage/secattach/20260223/26039890.html

Form 8-K Gossamer Bio, Inc. For: Feb 23

Mon, 23 Feb 2026 08:30:00 -0500

si-local-file:///var/storage/secattach/20260223/26039890.html

Gossamer Bio's seralutinib misses primary endpoint in PAH trial

Mon, 23 Feb 2026 08:00:36 -0500

Gossamer Bio Inc. (NASDAQ: GOSS) reported that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension failed to meet the primary endpoint's statistical threshold.

The trial showed a placebo-adjusted improvement in six-minute walk distance of 13.3 meters at week 24 with a p-value of 0.0320, missing the prespecified alpha threshold of 0.025. Patients receiving seralutinib had a median change of +28.2 meters from baseline, while placebo patients showed +13.5 meters.

The study enrolled 390 patients across treatment and placebo arms, with 55% on triple or quadruple background PAH therapy and 61% on background prostacyclin therapy.

In a prespecified subgroup of intermediate

Gossamer Bio's seralutinib misses primary endpoint in PAH trial

Mon, 23 Feb 2026 08:00:36 -0500

Gossamer Bio Inc. (NASDAQ: GOSS) reported that its Phase 3 PROSERA study of seralutinib for pulmonary arterial hypertension failed to meet the primary endpoint's statistical threshold.

The study enrolled 390 patients across treatment and placebo arms, with 55% on triple or quadruple background PAH therapy and 61% on background prostacyclin therapy.

In a prespecified subgroup of intermediate